Thought leadership calls for deep knowledge and insight. Driven by PharmSource’s decades of experience and evidence-based analysis, here we share industry and market insights and actionable recommendations for both buyers and sellers of bio/pharmaceutical contract services.

Using the Lead Sheet Icons to Identify Early Opportunities

Icons are everywhere! But don’t ignore the icons at the top of your weekly PharmSource Lead Sheet. These small symbols convey crucial information about drugs and financings being reported weekly in the Lead Sheet.

The I symbol denotes “Plans to initiate next-phase trial.” If your sweet spot is Phase II development and later, don’t ignore Phase I leads. You need to know…

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on Zynerba

Zynerba Pharmaceuticals raised $50.4 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know that they plan to use the proceeds to fund clinical trials with ZYN001 and ZYN002, including…

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on Clearside Biomedical

Clearside Biomedical plans to raise $36 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know that they plan to use the proceeds to continue early-stage R&D and…

Learn more

CRISPR: Gene Therapy 2.0

It looks like 2017 will be an exciting year for the Biotech industry. One development that has caught much attention is the new generation of gene therapy, the CRISPR-Cas9 genome editing tool that with cautious optimism is expected to start a new wave of faster, more accurate treatment for monogenetic diseases through DNA modification…

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on Synthetic Biologics, Inc.

Synthetic Biologics plans to raise $25 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know that they plan to use the proceeds to fund the clinical development of its pipeline, including…

Learn more

Biosimilars: Like Ryan Reynolds and Ryan Gosling

The FDA describes a biosimilar as a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, that has no clinically meaningful differences in terms of safety and effectiveness from the reference product. Only minor differences in clinically inactive components are…

Learn more